Publications by authors named "Cesar Molinero"
Background: Vafidemstat, an inhibitor of the histone lysine-specific demethylase KDM1A, corrects cognition deficits and behavior alterations in rodent models. Here, we report the results from the first-in-human trial of vafidemstat in healthy young and older adult volunteers. A total of 110 volunteers participated: 87 were treated with vafidemstat and 23 with placebo.
View Article and Find Full Text PDFFirst-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.
Olga Salamero Pau Montesinos Christophe Willekens José Antonio Pérez-Simón Arnaud Pigneux César Molinero
J Clin Oncol
December 2020
Article Synopsis
- Iadademstat is a new, powerful drug targeting LSD1 that shows promise in treating patients with relapsed/refractory acute myeloid leukemia (R/R AML) based on earlier studies.
- The study involved a phase I trial with 27 patients to assess the drug's safety, how it's processed in the body (pharmacokinetics), and its initial effectiveness, with a recommended dose determined at 140 µg/m/d.
- Results indicated that most side effects were manageable, and some patients showed reduced leukemia cells and signs of differentiation, leading to one case of complete remission, with further studies planned to explore combination treatments.